Jump to content

Radiation Oncology/NHL/NK T cell lymphoma

Add links
From Wikibooks, open books for an open world
< Radiation Oncology | NHL
This page may need to be reviewed for quality.

Front Page: Radiation Oncology | RTOG Trials | Randomized Trials

Non-Hodgkin lymphoma: Main Page | Randomized
Overview: Overview | Follicular | Diffuse large B-cell | MALT | Nodal marginal zone | Mantle cell | CLL/SLL | Lymphoblastic | Burkitt | NK/T cell | Anaplastic large cell | Primary CNS Lymphoma
Treatment: Aggressive | Specific sites | Radioimmunotherapy

Nasal NK/T lymphoma

[edit | edit source]

History

[edit | edit source]

Before 2000, NK/T lymphomas were not a clearly-defined entity and were lumped together with other lymphomas of the nasal cavity.

Clinical features

[edit | edit source]

NK cell has worse prognosis than B or T cell lymphoma.
Nasal lymphomas in Western populations have a better prognosis than in Asian countries. This may be due to a higher proportion of NK lymphomas or EBV-associated tumors in Asia.

  • Hong Kong, 1998 - PMID 9440725 — "Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients." Cheung MM et al. J Clin Oncol. 1998 Jan;16(1):70-7.
    • 113 pts.

Treatment

[edit | edit source]

Overview

[edit | edit source]

RT is recommended as the primary treatment. Consolidative CT should be considered for pts with adverse risk factors or Stage IIE disease.

Modality

[edit | edit source]
  • Japan, JCOG0211 - phase I/II
    • 33 pts total; 23 pts on phase II. Stage IE-IIE. Concurrent chemo/RT with 50 Gy and DeVIC (dexamethasone, etoposide, ifosfamide, carboplatin) x 3 courses.
    • 2009 PMID 19805668 -- "Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211." (Yamaguchi M, J Clin Oncol. 2009 Nov 20;27(33):5594-600.)
      • 27 pts treated to recommended dose from phase I. Median f/u 32 months. 2-yr OS 78%. (Historical control of RT alone: 45%) 77% with CR, 1 pt with PR.
    • Conclusion: chemo/RT is safe and effective
  • Korea - phase II
    • 30 pts. Stage IE-IIE. Concurrent chemo/RT with median 40 Gy and weekly cisplatin. Followed by 3 cycles of VIPD (etoposide, ifosfamide, cisplatin, dexamethasone).
    • 2009 PMID 19884539 -- "Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study." (Kim SJ, J Clin Oncol. 2009 Dec 10;27(35):6027-32.)
      • Response rate to cisplatin+RT: 100% (73% CR, 27% PR). Overall CR rate (after VIPD): 80%.
      • 3-yr PFS 85%, OS 86%.
    • Conclusion: recommend concurrent chemo/RT

Retrospective data:

  • Hong Kong, 1995 (1975-93) - PMID 7884427 — "Treatment outcome and prognostic factors for primary nasal lymphoma." Liang R et al. J Clin Oncol. 1995 Mar;13(3):666-70.
    • Retrospective. 100 pts. Various types (many were T-cell). RT alone or chemo->RT.
  • MDACC, 1997 (1947-93) - PMID 9241082 — "Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy." Logsdon MD et al. Cancer. 1997 Aug 1;80(3):477-88.
    • Note: per the Working Formulation, most were diffuse large cell type. Immunophenotype was not available for most patients.
    • Retrospective. 70 pts. Western population.
    • Improved FFP in those treated with CMT vs RT alone.
  • Hong Kong, 2002 (1977-2001) - PMID 12182990 — "Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality." Cheung MM et al. Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90.
    • All pts are NK/T (CD56+). 79 pts (61 chemo+RT, 18 RT alone). CR in 68.4%. Of those, 44% relapsed. 5-yr DFS 35.5%, OS 37.9%. No difference between those treated with RT alone vs combined modality.
  • South Korea, 2004 (1976-98) - PMID 15234048 — "Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints." Koom WS et al. Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1127-37.
    • 102 pts. RT alone to median dose of 45 Gy. 72% CR, but most of those experienced relapse, and 47% of all pts had local failure.
    • Conclusion: high local failure rate with RT alone. Plateau in dose response curve around 54 Gy.
  • China, 2005 (1983-2003) - PMID 16382127 — "Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma." Li YX et al. J Clin Oncol. 2006 Jan 1;24(1):181-9.
    • Retrospective. 105 pts. Stage IE and IIE. Pts received RT alone or combined modality. Initial RT resulted in CR of 83% vs CR of 20% for initial chemotherapy. OS and PFS were similar for RT alone and CMT.
    • Conclusion: recommend RT as primary therapy. Addition of CT does not lead to improved survival.

RT dose

[edit | edit source]

Doses >50 Gy are recommended.

References

[edit | edit source]
  • Review: PMID 9789607 (1998) - "Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification." Lopez-Guillermo A et al. Ann Oncol. 1998 Aug;9(8):849-55.
  • Review: PMID 9789605 (1998) No abstract - "Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas." Campo E et al. Ann Oncol. 1998 Aug;9(8):835-43.
  • Review: PMID 15233906 (2004) - "Treatment of T-cell non-Hodgkin's lymphoma." Evens AM et al. Curr Treat Options Oncol. 2004 Aug;5(4):289-303.
Retrieved from "https://en.wikibooks.org/wiki/Radiation_Oncology/NHL/NK_T_cell_lymphoma"